NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-AI-18-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to conduct research focused on elucidating mechanisms of Fc-dependent, antibody-mediated killing of infected or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. Studies supported by this FOA are expected to define variables that affect efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP), both in vitro and in vivo. U01 awardees will be expected to attend annual Program Progress/Steering Committee meetings and present progress to fellow awardees and to NIAID program staff. The goal of the meetings is to facilitate collaborations between funded investigators and to accelerate development of mechanistic models that incorporate the collective findings of this program. Advances in our understanding of these Fc-dependent killing mechanisms will inform more efficient design and optimization of ablative antibody therapeutics and may also inform design of vaccines that preferentially elicit ADCC- or ADCP-efficient antibody responses. This FOA uses the U01 grant mechanism, while the companion FOA, PA-19-xxx, uses the R21 mechanism. High risk/high reward projects with limited preliminary data or utilize existing data may be most appropriate for the R21 mechanism.
Funding Opportunity PA-19-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R21 applications for studies that address knowledge gaps in mechanisms of Fc-dependent, antibody-mediated killing of infected cells or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. More specifically, the purpose of this FOA is to promote innovative and exploratory research to elucidate mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), and to promote development of tools, technologies, and animal models to facilitate identification and evaluation of cytotoxic killing mechanisms mediated by human antibodies in vivo.
Funding Opportunity PAR-18-951 from the NIH Guide for Grants and Contracts. The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).
Funding Opportunity PAR-18-950 from the NIH Guide for Grants and Contracts. The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).
Funding Opportunity PAR-18-952 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Funding Opportunity PAR-18-953 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Funding Opportunity RFA-NS-19-011 from the NIH Guide for Grants and Contracts. The purpose of the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students who are from backgrounds that are nationally underrepresented in neuroscience research. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers.
Funding Opportunity RFA-OD-19-011 from the NIH Guide for Grants and Contracts. This FOA solicits applications for new Behavioral and Social Sciences Research (BSSR) predoctoral training programs that focus on innovative computational and/or data science analytic approaches and their incorporation into training for the future BSSR health research workforce. The vision of the Advanced Data Analytics for BSSR training program is to support the development of a cohort of specialized predoctoral candidates who will possess advanced competencies in data science analytics to apply to an increasingly complex landscape of behavioral and social health-related big data.
Funding Opportunity RFA-MH-19-210 from the NIH Guide for Grants and Contracts. A major goal of research on suicide is to improve our understanding of who is at most risk, why people transition from suicidal thoughts to action, and when to intervene (Prioritized Research Agenda for Suicide Prevention, Short-term Objective 1.C). Risk is a dynamic process and suicide attempts are often preceded by acute stressors. While many studies of suicide risk focus on emotion dysregulation, fewer studies have examined Arousal and Regulation and how these domains dynamically shape emotional and cognitive functions such as response to reward, frustrative non-reward, cognitive flexibility and control, or decision-making. Very few studies in the NIMH portfolio on suicide risk have focused on proximal risk. This FOA will fund research that will address these gaps, provide understanding of the mechanisms of how dysregulation interacts with Cognition, Negative and Positive Valence to determine time-varying risk, and identify modifiable targets for timely interventions during high risk periods. Applications submitted in response to this FOA must explicitly explore how interactions between at least one construct in the domain of Arousal and Regulation and one or more constructs in other RDoC domains are linked to imminent risk for suicide attempts. Studies that are focused solely on static suicidal traits, past behavior, or distal risk will not be considered responsive to this FOA, nor will studies that are solely focused on a single RDoC domain.
Funding Opportunity RFA-MH-19-211 from the NIH Guide for Grants and Contracts. A major goal of research on suicide is to improve our understanding of who is at most risk, why people transition from suicidal thoughts to action, and when to intervene (Prioritized Research Agenda for Suicide Prevention, Short-term Objective 1.C). Risk is a dynamic process and suicide attempts are often preceded by acute stressors. While many studies of suicide risk focus on emotion dysregulation, fewer studies have examined Arousal and Regulation and how these domains dynamically shape emotional and cognitive functions such as response to reward, frustrative non-reward, cognitive flexibility and control, or decision-making. Very few studies in the NIMH portfolio on suicide risk have focused on proximal risk. This FOA will fund research that will address these gaps, provide understanding of the mechanisms of how dysregulation interacts with Cognition, Negative and Positive Valence to determine time-varying risk, and identify modifiable targets for timely interventions during high risk periods. Applications submitted in response to this FOA must explicitly explore how interactions between at least one construct in the domain of Arousal and Regulation and one or more constructs in other RDoC domains are linked to imminent risk for suicide attempts. Studies that are focused solely on static suicidal traits, past behavior, or distal risk will not be considered responsive to this FOA, nor will studies that are solely focused on a single RDoC domain.
Funding Opportunity PA-18-935 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.
Funding Opportunity PAR-19-017 from the NIH Guide for Grants and Contracts. This program expansion FOA provides a mechanism for organizations receiving only Competition A funding under PAR-16-137 to apply for Competition B funding. Only those states/territories currently receiving funding for only Competition A under PAR-16-137 are eligible to apply.
Notice NOT-AT-19-001 from the NIH Guide for Grants and Contracts
Notice NOT-AI-18-055 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-053 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-003 from the NIH Guide for Grants and Contracts
Notice NOT-NR-18-020 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-055 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-056 from the NIH Guide for Grants and Contracts
Notice NOT-AI-18-060 from the NIH Guide for Grants and Contracts